Hennigsdorf/Berlin, Germany – July 31, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. SphingoTec develops and markets in-vitro diagnostic tests…Read more
Recent Posts by ruxandralenz
Endothelial dysfunction is driving pathophysiological processes such as congestion in heart failure, shock in sepsis, and lung dysfunction in COVID-19 Bioactive Adrenomedullin (bio-ADM®) is a proprietary biomarker for real-time assessment of endothelial function in acute and critical care settings. High blood levels of bio-ADM® have been shown to predict septic shock, to diagnose residual congestion…Read more
Results of a consensus meeting of clinical experts investigating sphingotec’s diagnostic solutions for acute and critical care in COVID-19. sphingotec’s biomarkers penKid, bio-ADM, and DPP3 previously shown to predict the need for organ support in numerous critical care conditions also have utility in risk stratification of severely ill COVID-19 patients. Hennigsdorf/Berlin, Germany, June 18, 2020…Read more
DPP3 is a highly dynamic marker for predicting and monitoring cardiac depression in burn patients High DPP3 blood concentrations are indicating multiple organ failure and poor outcomes sphingotec commercializes a rapid CE-IVD test for DPP3 on its proprietary point-of-care platform Nexus IB10 Hennigsdorf/Berlin, Germany, May 14, 2020 – Diagnostics company SphingoTec GmbH (“sphingotec”) and…Read more
Recent Comments by ruxandralenz
No comments by ruxandralenz yet.